Tirz3patide

Description

What Is Tirz3patide?

Tirz3patide is a synthetic pep developed as a dual agonist of glucagon‑like p3ptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP) receptors. This “twincretin” design represents a new generation of incretin‑based therapies, offering enhanced metabolic benefits compared to single‑pathway GLP‑1 agonists. It has been approved for type 2 diabetes management and is under investigation for obesity and related cardiometabolic conditions.

Mechanism of Action

Tirz3patide activates both GLP‑1 and GIP receptors. GLP‑1 receptor stimulation enhances glucose‑dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. GIP receptor activation further supports insulin secretion and may improve adipose tissue metabolism. Together, these pathways synergistically regulate glucose homeostasis, energy balance, and weight reduction. This dual mechanism provides superior efficacy compared to GLP‑1 agonists alone.

Research & Clinical Data

Clinical trials (SURPASS and SURMOUNT programs) demonstrated Tirz3patide’s remarkable efficacy in lowering HbA1c and promoting substantial weight loss, often exceeding results seen with S3maglutide. Patients achieved average body weight reductions of 15–20%, alongside improvements in cardiovascular risk factors and lipid profiles. FDA approval has been granted for type 2 diabetes, while obesity indications are under regulatory review. Reported side effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), with rare risks of pancreatitis. Contraindications include history of medullary thyroid carcinoma or MEN2 syndrome.

Purity & Quality

Pharmaceutical‑grade p3ptide. Certificate of Analysis available per batch. Regulatory status: FDA‑approved for type 2 diabetes; investigational for obesity.

Classification & Handling Class: Dual incretin agonist | Target: GLP‑1 and GIP receptors | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: FDA‑approved (diabetes), investigational (obesity)